The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

topazpharma.com

Total Raised

$20.5M

Investors Count

5

Deal Terms

1

Topaz Pharmaceuticals Funding, Topaz Pharmaceuticals Valuation & Topaz Pharmaceuticals Revenue

4 Fundings

Topaz Pharmaceuticals's latest funding round was a Acquired for on February 3, 2012.

Topaz Pharmaceuticals's valuation in November 2007 was $68.69M.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

2/3/2012

Acquired

0

FY undefined

1

12/17/2010

Series B

0

FY undefined

0

7/7/2010

Seed

$99M

0

FY undefined

0

11/19/2007

Series A

$99M

$68.69M

0

FY undefined

0

Date

2/3/2012

12/17/2010

7/7/2010

11/19/2007

Round

Acquired

Series B

Seed

Series A

Amount

$99M

$99M

Investors

Valuation

$68.69M

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

1

0

0

0

Topaz Pharmaceuticals Deal Terms

1 Deal Term

Topaz Pharmaceuticals's deal structure is available for 1 funding round, including their Series A from November 19, 2007.

Round

Series A

Funding Date

$99M

Pre-Money Valuation

Post-Money Valuation

Amount Raised

$99M

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$99M

Board Voting

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series A

$99M

$99M

$99M

$99M

Topaz Pharmaceuticals Investors

5 Investors

Topaz Pharmaceuticals has 5 investors. Sanofi Pasteur invested in Topaz Pharmaceuticals's Acquired funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

2/3/2012

2/3/2012

1
Acquired

Corporation

France

00/00/0000

00/00/0000

Aisling Capital

Subscribe to see more

Private Equity

New York

00/00/0000

00/00/0000

F-Prime Capital

Subscribe to see more

Venture Capital

Massachusetts

00/00/0000

00/00/0000

Ben Franklin Technology Partners of Southeastern PA

Subscribe to see more

Public-Private Partnership

Pennsylvania

00/00/0000

00/00/0000

Fidelity Investments

Subscribe to see more

Diversified Financial Services

Massachusetts

First funding

2/3/2012

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Last Funding

2/3/2012

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Investor

Aisling Capital

F-Prime Capital

Ben Franklin Technology Partners of Southeastern PA

Fidelity Investments

Rounds

1
Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Board Seats

Type

Corporation

Private Equity

Venture Capital

Public-Private Partnership

Diversified Financial Services

Location

France

New York

Massachusetts

Pennsylvania

Massachusetts

You May Also Like

E
Ectopharma

EctoPharma is a company developing therapeutic pesticides for specific healthcare and veterinary markets, for conditions such as the treatment of human head lice.

I
IVREA Pharmaceuticals

IVREA Pharmaceuticals is a specialty pharmaceutical company focused on clinical development and commercialization of novel prescription pharmaceuticals for the treatment of dermatologic conditions. IVREA's pharmaceuticals leverage topical delivery technologies.

C
Catena Pharmaceuticals

Catena Pharmaceuticals is focused on the development and commercialization of GPCR antagonists, particularly in the areas of cancer and fibrotic disease. Catena's chemistry is capable of affecting a specific class of GPCRs known to be relevant in a variety of disease states.

H
Humanetics Corporation

Humanetics Corporation is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs with a focus on radiation modulators for oncology, medical imaging and medical countermeasure uses.

A
Anza Therapeutics

Anza Therapeutics is developing active immunotherapies for the treatment of infectious diseases and cancer. Anza's therapeutic agents are based on its proprietary live-attenuated and Killed But Metabolically Active (KBMA) Listeria platforms which can be engineered to express antigens specific to the disease being treated.

P
P2D Biosciences

P2D, Inc. is a pharmaceutical company focused on developing new pharmaceuticals for brain disorders

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.